Skip to main content

Advertisement

Table 2 Effects of PPARα-agonists on triglycerides (TG) and high-density lipoprotein-cholesterol (HDL-C) levels

From: Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Compound Aleglitazar GFT505 K-877 Fenofibrate
Study SYNCHRONY[43, 44] S1[48] S2[48] K-877 P2[50] FIELD[12] K-877[50]
Dosage 150 μ g QD 80 mg QD 80 mg QD 100 μ g BID 200 mg QD 100 mg QD
Time point (weeks) 16 4 4 12 16 12
TG       
  Baseline (mg/dL) 157.7* 283.5 194.9 290.9 172.8 325.2
  Change vs. baseline NA −51.4 −62.9 NA NA NA
   (mg/dL)       
  % change vs. baseline −29.7** NA NA −41.4 NA −30.7
  % change vs. placebo −43.4** −16.7** −24.8** −69.9 −28.6 −59.2
HDL-C       
  Baseline (mg/dL) 46.8 34.8 46.4 40.9 42.5 40.1
  Change vs. baseline NA 2.7 3.1 NA NA NA
   (mg/dL)       
  % change vs. baseline 25.1** NA NA 16.9 NA 13.0
  % change vs. placebo 20.7** 7.8** 9.3** 18.2 5.1 14.3
  1. BID twice daily; NA, not available; QD once daily;
  2. Where necessary, values were multiplied by 88.6 for TG and by 38.67 for HDL-C to convert from mmol/L to mg/dL.
  3. Values are expressed as means unless otherwise stated.
  4. *Median.
  5. **Least squares means.